Skin-derived myeloid precursors and joint-resident fibroblasts spread psoriatic disease from skin to joints
- PMID: 41482544
- PMCID: PMC12764428
- DOI: 10.1038/s41590-025-02351-z
Skin-derived myeloid precursors and joint-resident fibroblasts spread psoriatic disease from skin to joints
Abstract
Psoriatic disease initially affects the skin and later extends to the joints. Here, we show a two-step process that orchestrates the spread of inflammation from the skin to the joints. Induction of psoriatic skin disease in photoconvertible mice, followed by sequencing and computational characterization of skin-derived cells in the joints, was used to identify a population of CD2+MHC-II+CCR2+ myeloid precursors that builds a skin-derived myeloid cell compartment in the joints. Single-cell cross-species reference mapping and mitochondrial variant tracing showed an orthologous human cell population. Interactome analysis of the joints showed that in a second step, resident regulatory CD200+ fibroblasts regulate the priming of CD2+MHC-II+CCR2+ myeloid precursors, which subsequently control IL-17 expression in T cells. Hence, the spread of inflammation requires a distinct migratory myeloid precursor population and a permissive local tissue environment, similar to tumor metastasis.
© 2026. The Author(s).
Conflict of interest statement
Competing interests: P.R. is employed by Cytek Biosciences, the maker of the Amnis brand ImageStream, which was used in this study. O.D. declares consultancy relationships with and/or has received research funding from and/or has served as a speaker for the following companies in the area of rheumatology in the past three calendar years: 4P-Pharma, Abbvie, Acepodia, Aera, AnaMar, Anaveon, Argenx, AstraZeneca, Boehringer Ingelheim, BMS, Calluna, Cantargia, CSL Behring, EMD Serono, Galderma, Galapagos, Gossamer, Hemetron, Innovaderm, Janssen, Lilly, MSD Merck, Nkarta, Novartis, Oorja Bio, Orion, Pilan, Prometheus, Quell, Redxpharma, Scleroderma Research Foundation, Sumitomo, Topadur, UCB and Umlaut bio. O.D. has a patent ‘mir-29 for the treatment of systemic sclerosis’ (US8247389, EP2331143) and is cofounder of CITUS. The other authors declare no competing interests.
Figures
References
-
- Veale, D. J. & Fearon, U. The pathogenesis of psoriatic arthritis. Lancet391, 2273–2284 (2018). - PubMed
-
- Tillett, W. et al. Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort. Rheumatology56, 2109–2113 (2017). - PubMed
-
- Alinaghi, F. et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J. Am. Acad. Dermatol.80, 251–265 (2019). - PubMed
-
- Sherlock, J. P. et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells. Nat. Med.18, 1069–1076 (2012). - PubMed
MeSH terms
Substances
Grants and funding
- RA 2506/7-1 and 493624887/Deutsche Forschungsgemeinschaft (German Research Foundation)
- 261193037/Deutsche Forschungsgemeinschaft (German Research Foundation)
- 391371888/Deutsche Forschungsgemeinschaft (German Research Foundation)
- 456565718/Deutsche Forschungsgemeinschaft (German Research Foundation)
- 424726560/Deutsche Forschungsgemeinschaft (German Research Foundation)
- 493624887/Deutsche Forschungsgemeinschaft (German Research Foundation)
- SO 1735/2-1/Deutsche Forschungsgemeinschaft (German Research Foundation)
- 853508/EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council)
- 810316/EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council)
LinkOut - more resources
Full Text Sources
Medical
Research Materials
